AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1

Covaxin Vaccine

Prescription Icon
Prescription Required

Marketer

Bharat Biotech

Salt Composition

Whole Virion, Inactivated Corona Virus vaccine (NA)

Overview Covaxin Vaccine

Containing the COVID-19 pandemic hinges on preventing SARS-CoV-2 infection. Covaxin, one of India's first domestically developed vaccines, received emergency authorization for individuals aged 18 and older. Jointly created by Bharat Biotech, the Indian Council of Medical Research (ICMR), and the National Institute of Virology (NIV) in Pune, its extensive clinical trials involved roughly 26,175 participants, representing India's largest such undertaking. Covaxin utilizes an inactivated virus, administered via intramuscular injection in the upper arm. This triggers an immune response that neutralizes future infections without causing illness. A two-dose regimen is required, with the second dose given four weeks after the first. Full antibody protection develops two weeks post-second dose; both doses are crucial. Phase 3 interim data indicated 81% efficacy; however, long-term protection remains undetermined. Continued preventative measures—mask use, frequent handwashing, social distancing, crowd avoidance, and daily health monitoring—are essential. Potential side effects, similar to other vaccines, include injection site reactions (pain, swelling, redness, itching), arm stiffness, headache, fever, malaise, nausea, vomiting, and rash. Most are transient (resolving within 2-3 days); paracetamol may alleviate symptoms. Consult a physician if symptoms persist or are concerning. Before vaccination, disclose all medical conditions, medications, and allergies. Individuals with fever, bleeding disorders, those on blood thinners or immunosuppressants, should postpone vaccination. Due to lack of trial data, this vaccine is not currently recommended for children, pregnant or breastfeeding women. Individuals who have already received another COVID-19 vaccine should not receive Covaxin.

Primary Ingredients of Covaxin Vaccine

The information is unavailable.

Uses of Covaxin Vaccine

Coronavirus disease (COVID-19) avoidance strategies

Major Benefits of Covaxin Vaccine:

Your healthcare provider will instruct you on the proper administration of this medication.

Common Side effects of Covaxin Vaccine:

  • Rash
  • Injection site reactions (pain, swelling, redness)
  • Headache
  • Fever
  • Feeling of discomfort
  • Nausea
  • Vomiting

How to use Covaxin Vaccine:

Your healthcare provider will instruct you on the proper administration of this medication.

How Covaxin Vaccine works:

Covaxin is a vaccine utilizing inactivated coronavirus particles. These killed viruses, rendered harmless, serve as antigens. Injection stimulates the immune system to develop a protective response against future coronavirus infections. The vaccine cannot cause the disease, yet effectively trains the body's defenses to combat the virus similarly to how the immune system responds to other illnesses, like influenza.

SAFETY ADVICE

AlcoholAlcoholCONSULT YOUR DOCTOR

Alcohol consumption alongside the Covaxin vaccine lacks established safety data. Physician consultation is recommended. Current expert opinion finds no evidence suggesting alcohol compromises vaccine efficacy.

PregnancyPregnancyCONSULT YOUR DOCTOR

Data on Covaxin's use in pregnancy are currently lacking. Seek medical advice from your physician.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Data on Covaxin's effects while breastfeeding are absent. Seek medical advice. Breastfeeding individuals should avoid this vaccine due to unstudied impacts on nursing mothers.

DrivingDrivingCONSULT YOUR DOCTOR

Covaxin's impact on driving ability is undetermined. Refrain from driving if you exhibit any symptoms impairing concentration or reaction time.

KidneyKidneyCONSULT YOUR DOCTOR

Insufficient data exists regarding Covaxin vaccination in individuals with renal impairment. Physician consultation is advised.

LiverLiverCONSULT YOUR DOCTOR

Data regarding Covaxin administration to individuals with hepatic impairment is scarce. Physician consultation is advised.

What if you forget to take Covaxin Vaccine :

Should you forget a Covaxin vaccination, seek your physician's advice.

Facts to Know About Covaxin Vaccine

LabelValue
Type of Compound Immunizations
Potential for Dependence None.
Type of Treatment Immunizations

FAQs on Covaxin Vaccine

Clinical studies of COVID-19 vaccines in pediatric populations are ongoing. Consequently, sufficient data to support their routine administration in children are currently lacking.
Following Indian government regulations, COVID-19 frontline personnel are to receive priority vaccination. Their family members, however, will be immunized based on the government's age-based vaccination schedule.
Confirmed. Vaccination is recommended for individuals with a past COVID-19 infection, barring contraindication from their physician. Prior infection, while offering some immunity, doesn't preclude the vaccine's benefit; it functions as an immune system enhancer. The documented occurrence of repeat COVID-19 infections further underscores the value of vaccination.
The Indian Drug Controller General has authorized a two-dose regimen for the Covaxin vaccine, with the second dose scheduled for 28 days after the initial injection. Concurrent research is exploring a potential booster shot, six months following the second dose. However, this booster protocol remains under review, pending completion of a limited government-sponsored clinical trial.
Confirmed. Current vaccines offer a significant degree of protection against emerging COVID-19 variants. Vaccination stimulates the production of diverse antibodies capable of neutralizing the virus. Existing evidence suggests that reported mutations are not likely to render the vaccines completely ineffective, providing continued protection against COVID-19.
No comparative analysis exists between India's Covishield and Covaxin vaccines; therefore, a definitive assessment of superiority is impossible. Both vaccines demonstrate efficacy in preventing COVID-19 infection across the population, notably among older individuals and those with pre-existing conditions like diabetes or hypertension.
Full immunity from the Covaxin vaccine typically develops within two to three weeks following the second dose.
Following Covaxin vaccination, minor reactions at the injection site—including pain, swelling, redness, or itching—along with headache, fever, general discomfort, nausea, vomiting, and skin rashes, may occur. These side effects are typically mild and self-limiting. Should symptoms persist, medical advice is recommended. Serious adverse events associated with Covaxin have not been documented.
Individuals with a history of anaphylaxis or allergic reactions to prior COVID-19 vaccinations, injectables, medications, or foods should avoid Covaxin. Furthermore, pregnant or breastfeeding women, and those unsure of their pregnancy status, are excluded from past COVID-19 vaccine trials and should not receive the Covaxin vaccine currently. Seek medical advice if you have any concerns.
Yes, the Covaxin vaccine has demonstrated safety and efficacy in adults managing hypertension, diabetes, chronic kidney disease, heart conditions, or lipid disorders. Individuals with these pre-existing health issues stand to gain the most from vaccination. Nevertheless, any concerns should prompt a consultation with your physician.
Prior to receiving the Covaxin vaccine, disclose to your physician any ongoing medications, their duration of use, and the conditions they treat. Report any allergies, fever, bleeding disorders, or use of blood thinners. Additionally, inform your doctor if you have a compromised immune system or are taking immunosuppressant medication. Pregnant or breastfeeding individuals should also seek medical consultation before vaccination. Previous COVID-19 vaccination should also be reported to your physician.
Covaxin requires storage and transport between 2° and 8° Celsius. India's cold chain system, encompassing roughly 29,000 locations, utilizes active and passive refrigeration to maintain the vaccine's required temperature.
The Co-WIN portal facilitates online registration and scheduling. Registration requires providing personal details and photo identification information. A single mobile number allows registration for up to four individuals; however, each person must supply their own photo ID.
Affirmative. Vaccination is possible without prior online registration. Consult a local government health professional for directions to the nearest COVID-19 Vaccination Centre (CVC) and its operating schedule. Bring your mobile phone and a photo ID for on-site registration, appointment scheduling, and same-day vaccination. CVC staff will assist with this process.
The Covaxin vaccine received Emergency Use Authorization following completion of required clinical testing.
Indian regulatory bodies, following international standards, may grant Emergency Use Authorization (EUA) for restricted use of specific vaccines, medications, or diagnostic tools. This authorization permits their deployment to combat serious public health threats, like the recent COVID-19 pandemic, for diagnosis, treatment, or prevention, even without full regulatory approval. This decision balances potential benefits against identified risks. Ongoing laboratory evaluations and clinical trials rigorously monitor the safety, efficacy, and quality of these interventions.
India's Drug Controller General of India (DCGI) has authorized five COVID-19 vaccines for emergency use: Covishield (AstraZeneca's vaccine produced by Serum Institute of India), Covaxin (from Bharat Biotech Limited), Sputnik V (Russia's vaccine, manufactured in India by Dr. Reddy's Laboratories), Moderna (an American vaccine imported by Cipla in India), and, most recently, Johnson & Johnson's single-dose vaccine.
The novel coronavirus SARS-CoV-2, responsible for the respiratory illness COVID-19, emerged as a human pathogen in 2019. COVID-19 is a rapidly transmissible viral infection characterized by respiratory distress, fever, and cough as primary clinical manifestations.
Clinical trials evaluating COVID-19 vaccines in children are ongoing. Consequently, insufficient data currently exists to support their use in this age group. This is due to the disproportionately higher morbidity and mortality rates observed in older individuals, especially those aged 50 and above. Neither currently available vaccine has undergone comprehensive safety and efficacy assessments in pediatric populations. Accordingly, administering COVID-19 vaccines to children is not recommended until sufficient evidence becomes available.
Following Indian government regulations, COVID-19 frontline personnel will receive priority vaccination. Other family members of these workers will be immunized based on the government's age-based prioritization schedule.
Individuals with a past COVID-19 infection should receive the vaccine, barring contrary advice from their doctor. Vaccination serves as an immunological boost, even after prior infection. The occurrence of repeat COVID-19 infections underscores the vaccine's significance.
The Indian Drug Controller General has authorized a two-dose regimen for the Covaxin vaccine, with the second dose scheduled 28 days after the initial vaccination. Further research is exploring a potential booster shot, six months following the second dose. However, this booster protocol remains tentative, pending completion of a small-scale government clinical trial.
Confirmed. Current vaccines offer substantial protection against emerging COVID-19 variants. Vaccination stimulates the production of diverse antibodies, capable of neutralizing the virus. Existing evidence suggests that reported mutations are not expected to render the vaccines ineffective, thus maintaining their protective efficacy against COVID-19.
In India, a comparative analysis of Covishield and Covaxin vaccines is absent, precluding definitive conclusions on efficacy superiority. Both vaccines demonstrate effectiveness against COVID-19 infection across all recipients, especially the elderly and those with pre-existing conditions like diabetes or hypertension.
Full immunity from the Covaxin vaccine typically develops within two to three weeks following the second dose.
Following Covaxin vaccination, minor reactions at the injection site—including soreness, inflammation, redness, and itching—along with headache, fever, general discomfort, nausea, vomiting, and skin rashes, may occur. These are typically mild and self-limiting, resolving spontaneously. Persistent symptoms warrant medical attention. Serious adverse events have not been documented following Covaxin administration.
Individuals with a history of anaphylaxis or allergic reactions to prior COVID-19 vaccinations, injectables, medications, or food should avoid Covaxin. Pregnant or breastfeeding women, and those unsure of their pregnancy status, are not included in existing COVID-19 vaccine trials and should not receive the vaccine currently. Consult your physician if you have any concerns.
Yes, the Covaxin vaccine has demonstrated safety and efficacy in adults managing hypertension, diabetes, chronic kidney disease, heart conditions, or lipid disorders. Individuals with these pre-existing health issues may experience the greatest advantage from vaccination. Nevertheless, consult your physician if you have any specific concerns.
Prior to receiving the Covaxin vaccination, disclose to your physician any ongoing medications, their duration, and the conditions they treat. Report any allergies, fever, bleeding disorders, anticoagulant use, immunodeficiency, or medications impacting your immune system. Pregnant or breastfeeding individuals should seek medical counsel before vaccination. Additionally, inform your doctor of any prior COVID-19 vaccinations.
Covaxin requires refrigeration between 2° and 8° Celsius during storage and transport. India's cold chain infrastructure, encompassing roughly 29,000 points, utilizes active and passive cooling systems to maintain the necessary temperature for Covaxin distribution.
The Co-WIN website facilitates online registration and appointment scheduling. Registration requires providing personal details and photo ID information. A single mobile number can register up to four individuals; each person must supply their own photo identification.
Affirmative. Vaccination is possible without prior online registration. Inquire with a local public health professional for directions to a nearby COVID-19 vaccination center and its operating schedule. Bring your mobile phone and a photo ID for on-site registration, appointment scheduling, and immediate vaccination. Center staff will assist with this process.
The Covaxin vaccine received emergency use authorization following completion of required clinical testing.
Conditional authorization, mirroring international standards, permits Indian regulatory bodies to enable the use of specified vaccines, drugs, or diagnostic tools for treating, preventing, or diagnosing serious health crises (like the recent COVID-19 pandemic). This temporary allowance, issued during public health emergencies, balances potential benefits against identified risks, even without full regulatory approval. Ongoing laboratory analysis and clinical studies continuously monitor the safety, efficacy, and quality of these medical interventions.
India's Drug Controller General of India (DCGI) has authorized emergency use for five COVID-19 vaccines: Covishield (AstraZeneca's vaccine produced by the Serum Institute of India), Covaxin (Bharat Biotech Limited), Sputnik V (a Russian vaccine manufactured in India by Dr. Reddy's Laboratories), Moderna (an American vaccine imported into India by Cipla), and, most recently, Johnson & Johnson's single-dose vaccine.
The novel coronavirus SARS-CoV-2, responsible for the respiratory illness COVID-19, emerged as a human pathogen in 2019. COVID-19 is a rapidly spreading, highly contagious viral infection. Characteristic symptoms in affected individuals commonly include fever, cough, and shortness of breath.
Covaxin Vaccine
215
MRP 250
14% off